Dr. Michael J. O’Neill
Dr. O’Neill received a doctorate in pharmacology from University College in Galway, Ireland and later joined Eli Lilly & Co. where he worked for 24 years. He held a variety of roles, led several drug discovery efforts and managed a variety of teams at Lilly. From 2014-2018 he was the Head of the Molecular Pathology Group at Lilly UK where he led a team of 25-28 in vitro and in vivo scientists working on novel treatments for AD and PD. He is currently a Senior Director of Drug Discovery Biology and Senior Research Fellow at AbbVie, Ludwigshafen, Germany.
He has a strong background in Neurodegenerative disease research and has worked extensively on Stroke and more recently focused on disease modifying approaches for both Alzheimer’s Disease (AD) and Parkinson’s Disease (PD). He also has a keen interest in tauopathies (PSP and FTD) and previously led the ALS research efforts at Lilly.
O’Neill has acted as industrial supervisor for 21 graduate students, 12 PhD students and several post-doctorate scientists. He has regularly presented (77 invited oral presentations) at international conferences and academic institutes. He has been an associate editor for the Journal of Pharmacology and Experimental Therapeutics and has published more than 127 scientific articles. He is a member of the ARUK Grants Review Board and is a reviewer for multiple journals and grant bodies.